February 5, 2021

February 5, 2021 – UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, has announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $8M, before deducting the underwriting discounts and commissions and offering expenses. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021 with the offering expected to close on February 9, 2021. In addition to the shares being sold in the IPO, Angion has agreed to sell an additional 1,562,500 shares of its common stock in a concurrent private placement at at a public offering price of $16.00 per share to entities affiliated with Vifor International, Ltd., an existing stockholder.

Read the full release here.